It targets fat cells, particularly in visceral adipose tissue, and enhances insulin sensitivity, ultimately aiding in the reduction of excess weight
If you cannot reach the area comfortably, stick to your abdomen or thigh
Because semaglutide does not act on the GIP receptor at all, this variant had no effect on semaglutide tolerability whatsoever
Other side effects, like hair loss, may begin later into the treatment, usually after a few months and following significant weight loss
It is specifically contraindicated for individuals with: A personal or family history of medullary thyroid carcinoma (MTC), based on findings of thyroid C-cell tumours in animal studies Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Type 1 diabetes or diabetic ketoacidosis semaglutide is not designed for this purpose Pregnancy, or plans to become pregnant within the next 2 months (semaglutide should be discontinued at least 2 months before attempting conception) Age under 12 years (Wegovy is approved from age 12 only for severe obesity, under specialist supervision) Additional caution is needed for patients with a history of pancreatitis, gallbladder disease, diabetic retinopathy, or significant kidney impairment these patients require closer monitoring throughout treatment
